A Decisive Review to Understand the Basic Fundamentals of Novel Corona Viruse Disease

S. Sweta, Navdeep Singh
{"title":"A Decisive Review to Understand the Basic Fundamentals of Novel Corona Viruse Disease","authors":"S. Sweta, Navdeep Singh","doi":"10.52711/2321-5836.2021.00024","DOIUrl":null,"url":null,"abstract":"With the development and spread of 2019 novel coronavirus (2019-nCoV), also known as the severe acute respiratory syndrome coronavirus 2, a new public health disaster is threatening the world (SARS-CoV-2). In December 2019, the virus was discovered in bats and transmitted to humans via unidentified intermediary species in Wuhan, Hubei Province, China. To date (05/03/2020), there have been roughly 96,000 recorded cases of coronavirus disease 2019 (COVID-2019) and 3300 documented deaths. The disease is spread through inhalation or contact with contaminated droplets, with a 2 to 14-day incubation period. Fever, cough, sore throat, dyspnea, weariness, and malaise are common symptoms. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it can lead to pneumonia, ARDS (acute respiratory distress syndrome), and multi-organ failure. A large number of persons are asymptomatic. The case fatality rate is expected to be between 2 and 3%. Specimen collection, assay collection, serology, nucleic acid testing or molecular testing, and target selection for RT-PCR are all examples of laboratory diagnosis. Home isolation of suspected cases and those with mild illnesses, as well as tight infection control measures in hospitals, including contact and droplet precautions, are all part of the prevention strategy. The virus has a lower fatality rate than its two ancestors, SARS-CoV and Middle East respiratory sickness coronavirus (MERS-CoV). The global consequences of this new epidemic are still unknown.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Pharmacology and Pharmacodynamics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/2321-5836.2021.00024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

With the development and spread of 2019 novel coronavirus (2019-nCoV), also known as the severe acute respiratory syndrome coronavirus 2, a new public health disaster is threatening the world (SARS-CoV-2). In December 2019, the virus was discovered in bats and transmitted to humans via unidentified intermediary species in Wuhan, Hubei Province, China. To date (05/03/2020), there have been roughly 96,000 recorded cases of coronavirus disease 2019 (COVID-2019) and 3300 documented deaths. The disease is spread through inhalation or contact with contaminated droplets, with a 2 to 14-day incubation period. Fever, cough, sore throat, dyspnea, weariness, and malaise are common symptoms. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it can lead to pneumonia, ARDS (acute respiratory distress syndrome), and multi-organ failure. A large number of persons are asymptomatic. The case fatality rate is expected to be between 2 and 3%. Specimen collection, assay collection, serology, nucleic acid testing or molecular testing, and target selection for RT-PCR are all examples of laboratory diagnosis. Home isolation of suspected cases and those with mild illnesses, as well as tight infection control measures in hospitals, including contact and droplet precautions, are all part of the prevention strategy. The virus has a lower fatality rate than its two ancestors, SARS-CoV and Middle East respiratory sickness coronavirus (MERS-CoV). The global consequences of this new epidemic are still unknown.
了解新型冠状病毒病基本原理的决定性综述
随着新型冠状病毒(2019- ncov)的发展和传播,一场新的公共卫生灾难(SARS-CoV-2)正在威胁世界。2019年12月,该病毒在中国湖北省武汉市的蝙蝠中被发现,并通过身份不明的中间物种传播给人类。到目前为止(2020年3月5日),已经记录了大约96000例2019年冠状病毒病(COVID-2019)病例和3300例记录的死亡病例。该病通过吸入或接触受污染的飞沫传播,潜伏期为2至14天。发烧、咳嗽、喉咙痛、呼吸困难、疲倦和不适是常见的症状。这种疾病对大多数人来说是轻微的;在某些情况下(通常是老年人和有合并症的人),它可导致肺炎、急性呼吸窘迫综合征(ARDS)和多器官衰竭。很多人没有症状。病死率预计在2%至3%之间。标本收集、化验收集、血清学、核酸检测或分子检测以及RT-PCR的靶标选择都是实验室诊断的例子。在家中隔离疑似病例和轻症患者,以及在医院采取严格的感染控制措施,包括接触和飞沫预防措施,都是预防策略的一部分。该病毒的致死率低于其两个祖先,即SARS-CoV和中东呼吸系统疾病冠状病毒(MERS-CoV)。这种新流行病的全球后果仍然未知。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信